Results 151 to 160 of about 1,489,579 (226)

A Disproportionality Analysis of β‐lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims β‐lactam antibiotics stand as the most profoundly impactful classes of antibacterial agents worldwide. Their widespread application has raised safety concerns over adverse events (AEs), such as blood and lymphatic system disorders (BLSDs).
Jing Liu, Min Zhang, Zongwei Tang, Xiaoxiao Wang, Li Mu, Wanyi Chen, Haichi Song   +6 more
wiley   +1 more source

Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy. [PDF]

Antibiotics (Basel)
Grossman JM, Thompson DK.
europepmc   +1 more source

Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations

ObjectivesAn Escherichia coli isolate, WGS1363, showed resistance to piperacillin/tazobactam but susceptibility to cephalosporins and contained a previously unrecognized β-lactamase, CTX-M-255, as the only acquired β-lactamase. CTX-M-255 was identical to
Warweitzky, Jakob K, Rick, Tim, Warweitsky, Jakob K, Häussler, Susanne, Schønning, Kristian, Andreasen, Minna Rud, Pedersen, Martin Schou, Jelsbak, Lotte, Botelho, Carolina M, Botelho, Carolina Mastella, Hansen, Katrine Hartung, Alexandersen, Nicolai R., Alexandersen, Nicolai Riff, Schou Pedersen, Martin   +13 more
core   +1 more source

Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract There are currently no oral treatment options for infections caused by extended spectrum β‑lactamase‐producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections ...
Siddhee A. Sahasrabudhe, Satoshi Shoji, Abhijeet S. Jakate, Bisrat K. Abraham, Sima S. Toussi, Benjamin J. Maligalig, Amanda S. Darekar, Sakambari Tripathy, Constantino Kantaridis, Josue K. Mfopou, Oxana Selivanova, Arthur Bergman, Negar Niki Alami, Ravi Shankar P. Singh   +13 more
wiley   +1 more source

<i>In vitro</i> activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. [PDF]

JAC Antimicrob Resist
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, Okade H, Mikamo H.   +7 more
europepmc   +1 more source

Detecting Antibiotic Resistance in Strains of Selected Gram‐Negative Bacterial Species Using Raman Spectroscopy

Journal of Raman Spectroscopy, Volume 57, Issue 9, Page 1554-1564, September 2026.
Raman spectroscopy successfully identified antibiotic‐resistant Gram‐negative strains. Resistant strains of four bacterial species were discriminated from sensitive ones with 99.1% accuracy using PLS regression. The method allows for rapid, label‐free detection of antibiotic resistance.
Fernanda Sant Ana de Siqueira e Oliveira, Adriano Moraes da Silva, Marcos Tadeu T. Pacheco, Landulfo Silveira Jr.   +3 more
wiley   +1 more source

Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults. [PDF]

Antimicrob Agents Chemother
Morita J, Ishiwata K, Matsumoto S, Kato S, Attley G, Patel K, Rodriguez I, Mallalieu NL.   +7 more
europepmc   +1 more source

Microbial Signals in Cancer: Dissecting Host–Microbiota–Tumor Interactions and Potential Therapeutic Strategy

MedComm, Volume 7, Issue 9, September 2026.
Microbial signals from gut and tumor‐resident bacteria, fungi, viruses, and bacteriophages reshape immune and metabolic networks within the tumor microenvironment, thereby influencing cancer progression, treatment response. Therapeutic modulations, including dietary interventions, probiotics, antibiotics, fecal microbiota transplantation, engineered ...
Juan Lu, Mengjuan Xuan, Liang Yu, Zhongyang Xie, Qingfei Chu, Shihui Wei, Tuokai Wang, Chen Xue, Lanjuan Li   +8 more
wiley   +1 more source

Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection. [PDF]

JAC Antimicrob Resist
Morita J, Ishiwata K, Matsumoto S, Kato S, Attley G, Patel K, Rodriguez I, Mallalieu N.   +7 more
europepmc   +1 more source

Development of a Gold Nanoparticle‐Assisted Multiplex Polymerase Chain Reaction Assay for Selected Hospital‐Acquired Infections‐Associated Bacterial and Fungal Pathogens

ChemistryOpen, Volume 15, Issue 9, September 2026.
Gold nanoparticle‐assisted multiplex PCR enables the simultaneous detection of six major hospital‐acquired infection‐associated pathogens by improving amplification performance and assay specificity, providing an analytical proof‐of‐concept for rapid molecular identification.
Kubra Aslan, Emre Erden Kopar, Serap Evran   +2 more
wiley   +1 more source